EGFR and non-small cell lung carcinoma: Despite a small sample size due to the limitation that EGFR-mutant patients are not recommended to receive ICIs treatment, our findings are still meaningful and interesting and might provide some hints for further studies and potential directions for development of ICIs treatment for EGFR-mutant NSCLC.